Recent Posts
- MicroRNA-Mediated Metastasis Suppression
- A New Explanation Of ‘Asian Paradox’
- Toward Bold New Anti-cancer Medicines
- Celsion And Yakult Honsha Announce Treatment Of First Patient In Japan In Celsion’s Global Phase III ThermoDox(R) Trial For Primary Liver Cancer
- $6.5 Million Gift To UCSF From Irwin And Joan Jacobs For Head And Neck Cancer Research
Random Posts
- Government Of Canada Approves A New Source Of Medical Isotopes
- Close Surveillance Benefits Both Early- and Late-Stage Colon Cancer (CME/CE)
- Low Vitamin D Levels In Blacks Could Contribute To Higher Rates Of Cancer, Other Diseases, Researcher Says
- Home Interventions Could Benefit Cancer Survivors
- New Diet And Exercise Guidelines For Prostate Health Published By Prostate Cancer Foundation
- American Association For Cancer Research Announces New Editor-in-Chief Of Cancer Research
- Cancer Deaths Second Only to Suicide in Schizophrenia (CME/CE)
- Prostate Cancer Death Unlikely After Prostatectomy (CME/CE)
- Discovery Of Gene Mutation Responsible For Hereditary Neuroendocrine Tumor
- CIN, Cervical Cancer Risk Persist Despite Treatment (CME/CE)
Prescription Cancer Drugs
Cancer Therapies: How Much Is Life Worth? The $440 Billion Question
Posted by: admin in Prescription Cancer Drugs on July 01st, 2009
The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online June 29 in the Journal of the National Cancer Institute.
Tito Fojo, M.D., Ph.D., of the Medical Oncology Branch, Center of Cancer Research at the National Cancer Institute, in Bethesda, Md., and Christine Grady, Ph.D., of the Department of Bioethics, the Clinical Center at the National Institutes of Health, tackle the controversy concerning the life-extending benefits of certain cancer drugs and the extent to which their cost should factor in deliberations.
The authors illustrate cost-benefit relationships for several cancer drugs, including cetuximab for treatment of non-small cell lung cancer, touted as “practice changing” and new standards of care by professional societies, including the American Society of Clinical Oncology.
They ask, “Is an additional 1.7 months [the additional overall survival for colorectal cancer patients treated with cetuximab] a benefit regardless of costs and side effects?”
According to Fojo and Grady, in the U.S., 18 weeks of cetuximab treatment for non-small cell lung cancer, which was found to extend life by 1.2 months, costs an average of $80,000, which translates into an expenditure of $800,000 to prolong the life of one patient by 1 year. At this rate, it would cost $440 billion annually, an amount 100 times NCI’s budget, to extend the lives of 550,000 Americans who die of cancer annually by 1 year.
To address the issue, the commentators recommend that studies powered to detect a survival advantage of two months or less should test only interventions that can be marketed at a cost of less than $20,000 for a course of treatment.
Every life is of infinite value, the authors say, but spiraling costs of cancer care makes this dilemma inescapable.
“The current situation cannot continue. We cannot ignore the cumulative costs of the tests and treatments we recommend and prescribe. As the agents of change, professional societies, including their academic and practicing oncologist members, must lead the way,” the authors write. “The time to start is now.”
Citation: Fojo T. and Grady C. How Much Is Life Worth: Cetuximab, Non - Small Cell Lung Cancer, and the $440 Billion Question J Natl Cancer Inst 2009, 101: 1-5.
Source:
Steve Graff
Journal of the National Cancer Institute
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.